The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

• On April 2, Edgewise Therapeutics priced an underwritten public offering of 9.94 million shares at $20.13 per share, expecting to raise approximately $200 million. The offering is set to close on April 3, pending customary conditions. The company's stock fell around 55% over the past month and has a 52-week low of $10.60.
• RSI Value: 27.5
• EWTX Price Action: Shares of Edgewise Therapeutics gained 8.8% to close at $12.50 on Wednesday.
• Edge Stock Ratings: 15.43 Momentum score.

• On Feb. 7, HC Wainwright & Co. analyst Ed Arce reiterated Genfit with a Buy rating and maintained a $13 price target. The company's stock fell around 27% over the past five days and has a 52-week low of $2.55.
• RSI Value: 29.3
• GNFT Price Action: Shares of Genfit dipped 21.4% to close at $2.64 on Wednesday.
• Benzinga Pro’s charting tool helped identify the trend in GNFT stock.

• On March 27, CalAmp reported a quarterly loss of $11.04 per share which met the analyst consensus estimate. “We are off to a strong start in 2025, building on the momentum of a successful 2024, which included advancing our Phase 1 clinical program in UCDs, establishing key research collaborations, securing important regulatory designations, and completing our initial public offering,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. The company's stock fell around 49% over the past month and has a 52-week low of $0.39.
• RSI Value: 23.1
• CAMP Price Action: Shares of CAMP4 Therapeutics dipped 7.4% to close at $2.14 on Wednesday.
• Benzinga Pro’s signals feature notified of a potential breakout in CAMP shares.